A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 10/6/2018 |
| Start Date: | August 22, 2011 |
| End Date: | May 2021 |
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
The goal of this study is to determine the feasibility and safety of treating patients with a
brain tumor known as craniopharyngioma with limited surgery and a 5mm clinical target volume
margin in combination with proton therapy. Proton therapy will be indicated for patients with
diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection).
Irradiated patients will undergo a series of evaluations designed to evaluate the effects of
proton therapy. Similar evaluations will be performed on patients treated with radical
surgery. Proton therapy will include 30 treatment fractions administered 5 days per week.
Weekly imaging will be a requirement to monitor for cyst expansion and target volume
deformation.
brain tumor known as craniopharyngioma with limited surgery and a 5mm clinical target volume
margin in combination with proton therapy. Proton therapy will be indicated for patients with
diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection).
Irradiated patients will undergo a series of evaluations designed to evaluate the effects of
proton therapy. Similar evaluations will be performed on patients treated with radical
surgery. Proton therapy will include 30 treatment fractions administered 5 days per week.
Weekly imaging will be a requirement to monitor for cyst expansion and target volume
deformation.
The primary objectives of this study :
To estimate the progression-free and overall survival distributions for children and young
adults with craniopharyngioma treated with limited surgery and proton therapy using a 5mm
clinical target volume margin while monitoring for excessive central nervous system necrosis.
The Secondary Objectives of this study:
- To estimate the cumulative incidence of cystic intervention and the event-free survival
distribution for children and young adults with craniopharyngioma treated with limited
surgery and proton therapy using a 5mm clinical target volume margin; and compare the
distributions of progression-free, event-free and overall survival with the
distributions for the St. Jude Children's Research Hospital cohort of 93 patients on
which the design of this trial is based.
- To estimate the distributions of progression-free survival and overall survival for
children and young adults with craniopharyngioma treated only with primary surgical
resection and to compare these distributions with the distributions observed for
patients treated with limited surgery and proton therapy.
To estimate the progression-free and overall survival distributions for children and young
adults with craniopharyngioma treated with limited surgery and proton therapy using a 5mm
clinical target volume margin while monitoring for excessive central nervous system necrosis.
The Secondary Objectives of this study:
- To estimate the cumulative incidence of cystic intervention and the event-free survival
distribution for children and young adults with craniopharyngioma treated with limited
surgery and proton therapy using a 5mm clinical target volume margin; and compare the
distributions of progression-free, event-free and overall survival with the
distributions for the St. Jude Children's Research Hospital cohort of 93 patients on
which the design of this trial is based.
- To estimate the distributions of progression-free survival and overall survival for
children and young adults with craniopharyngioma treated only with primary surgical
resection and to compare these distributions with the distributions observed for
patients treated with limited surgery and proton therapy.
Inclusion Criteria:
- Craniopharyngioma diagnosed by histology, cytology or neuroimaging.
- Patients ages 0-21 years at the time of diagnosis.
Exclusion Criteria
- Prior history of fractionated radiation therapy.
- Prior treatment with intracystic P-32, intracystic bleomycin or radiosurgery.
- Pregnant females are excluded. Radiation has teratogenic or abortifacient effects.
We found this trial at
2
sites
Jacksonville, Florida 32206
Principal Investigator: Daniel J. Indelicato, MD
Phone: 904-588-1442
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Thomas E Merchant, DO, PhD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials